Phase I/IIa study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin's lymphoma

Timothy Illidge

Research output: Contribution to journal › Article › peer-review

Original languageEnglish
JournalBlood Advances
Publication statusAccepted/In press - Jun 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-being

Cite this